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Abstract
During the past decade, distributed ledger
technology (DLT) has found its way into application
areas outside finance, such as supply chain
management, the Internet of Things, or health care. To
this end, this novel technology phenomenon has recently
also caught the attention of researchers and
practitioners in genomics. Although various DLT-based
data markets for genome data already exist or are in
development, the potential of DLT in this context is far
from exhausted, whereas the possible risks related to the
application of DLT in genomics are not yet sufficiently
known. In this work, we investigate the potential
opportunities and challenges for the application of DLT
in the field of genomics. Thus, we make an important
contribution to the safe and socially acceptable use of
DLT in this unique and highly relevant use context.

1. Introduction
Distributed Ledger Technology (DLT) is one of the
most hyped information technology innovations of the
last decade that is probably best known for the
cryptocurrency Bitcoin and its underlying DLT concept
Blockchain [1]. Yet, the hype around DLT nowadays
extends far beyond applications in the financial sector,
with potential benefits of DLT being discussed in
diverse industries and application scenarios, including
supply chain management, the Internet of Things, and
especially health care [2]. Often cited benefits of DLT
pertain to enabling secure transactions between
untrustworthy parties through automated, algorithmbased consensus building mechanisms, which eliminate
the need for third-party trust enforcement [1], high
availability of DLT-based systems [3], or the ability to
automate and enforce processes by means of smart
contracts [4].
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Recently, DLT has also caught the interest of
practitioners and researchers within the field of
genomics [4-6]. Thereby, the diffusion of DLT in
genomics is currently mainly driven by a small but
rapidly increasing number of businesses such as Nebula
Genomics, EncrypGen, or LunaDNA (see section 2.2
for a more detailed overview of DLT genomics
businesses). In most cases, the objective of these
businesses is to operate data markets, where users can
share their genome data with third parties in exchange
for tokens. Accordingly, DLT quickly gained the
interest of the genomics community, as it promises to
facilitate the exchange of genomic data and offers
opportunities to reward data providers (e.g. through the
use of tokens). However, to date, the majority of these
initiatives is still in a pre-market phase. Furthermore,
and despite the promising potential of DLT, applications
of DLT have so far only been successfully implemented
and operated in a limited number of cases. For example,
only 8% of the DLT-related projects on GitHub are
actively maintained [7].
Researchers within the field of genomics and
associated disciplines have only recently begun to
investigate the full potential of DLT for the genomics
research community and other relevant stakeholders in
genomics (e.g., genome data donors, medical
professionals, pharma industry) [4, 6]. Due to the
novelty of DLT for the genomics community, we still
lack a profound understanding of what specific
opportunities the application of DLT can bring forth for
genomics, beyond the mere creation of genome data
markets. Even more so, extant literature and,
unsurprisingly, also white papers of involved businesses
paint a rather positive picture of the prospective
opportunities for DLT in genomics. To this end, the
potential challenges that the application of DLT in
genomics can bring forth are barely considered in the
ongoing discussions about the utility of DLT for the
genomics community. Overall, we as a community still
lack knowledge on what are the most promising
opportunities as well as the most demanding challenges
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related to the application of DLT in genomics. We
therefore ask the following research questions:
RQ1: What are opportunities and challenges for the
application of DLT in genomics?
RQ2: What is the relative importance of the identified
opportunities and challenges?
To answer our research questions, we conduct a
ranking-type Delphi study with an international panel of
experts on genomics and/or DLT and augment the
results of the Delphi process with insights from a review
of white papers and scientific publications on DLT in
genomics. In doing so, the opportunities and challenges
for the application of DLT in genomics that are
described in this work present an important contribution
to research and practice as they lay the foundation for
directing adoption efforts towards the most promising
opportunities as well as the most demanding challenges.
The remainder of this paper is structured as follows.
In section two, we provide a brief introduction to DLT
and an overview of the current state concerning the
application of DLT in genomics. In section three, we
detail on our research approach, including panel
selection and the employed ranking-type Delphi
method. Section four presents our results in terms of
identified opportunities and challenges as well as their
relative rankings, before we discuss our results in
section five. We conclude the paper in section six.

2. Related research
2.1 Distributed Ledger Technology
DLT is an emerging technology that enables the
operation of a distributed ledger, which is a special type
of an append-only, distributed database that is
particularly suited to the peculiarities of an
untrustworthy environment [8, 9]. Inherent to DLT is
the creation of a ledger that is replicated in a network of
storage devices, which are referred to as nodes.
Compared to traditional distributed databases, such
structure allows for the presence of Byzantine failures.
Byzantine failures include the presence of crashed or
unreachable nodes, network delays, or malicious
behavior of nodes [8]. In DLT, new data is added to the
ledger using transactions that are committed on each
node’s replication [e.g., 10]. The data is then stored in a
well-defined structure. Through the use of
cryptographic techniques (e.g., hashing), data stored in
the distributed ledger can hardly be removed or
modified, resulting in near immutability. Each DLT
design (e.g., Bitcoin [10]) employs a consensus
mechanism to reach consistency between the

replications stored on nodes of the distributed ledger. A
consensus mechanism is an algorithm used to negotiate
the valid state between nodes of the distributed ledger.
Consensus mechanisms employ trust models, which
consider threats and uncertainties in the process of
consensus finding (e.g., Byzantine failures [8]). DLT
can be employed to operate a distributed infrastructure
across multiple parties, who can develop applications on
DLT. Such applications on DLT make use of so-called
smart contracts. Smart contracts are computer programs,
which contain formalized business processes (e.g.,
conditional withdrawals) and are deployed and executed
on a distributed ledger [e.g., 11]. Smart contracts can
also retrieve data from the respective distributed ledger
itself (on-chain) or from the external world (off-chain).
Off-chain data feeds, which can be called by a smart
contract to retrieve data are called oracles.

2.2. Distributed Ledger Technology in
genomics
Genomics is the scientific discipline concerned with
the sequencing, mapping, and analysis of genomes [12].
It is an integral part of contemporary (bio-)medical
research and the ongoing shift towards a precision
medicine treatment paradigm in health care [13].
Following the completion of the Human Genome
Project, advances in genome sequencing, mapping, and
analysis technologies have led to plummeting costs for
the acquisition of genome data, from costs of around
USD 95 million per whole genome sequence in 2001 to
costs of around USD 1,300 per whole genome sequence
today [14]. However, with the availability of relatively
inexpensive means for acquiring and analyzing genome
data on the one hand and the inherent characteristics of
genome data (e.g., uniqueness, kinship, staticity) on the
other hand [15], a variety of ethical, legal, and social
challenges have emerged [16, 17]. Such challenges
include, for example, trade-offs between individuals’
right to privacy and the overall benefit of freely sharing
genome data [16], interdependent privacy due to kinship
[18], individuals’ ability to comprehend and interpret
the results of genetic testing [19], or the handling of
inadvertent findings [20].
Employing DLT within genomics promises to
address many of the aforementioned ethical, legal,
social challenges [4, 6]. However, since the application
of DLT in genomics is still in its infancy, DLT’s
diffusion within the community is currently to a large
degree driven by a small but rapidly increasing number
of young businesses. One of the pioneering and most
prominent businesses in this area being Nebula
Genomics. Like most players in the commercial DLT-
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Table 1. Excerpt of DLT genomics businesses.
DLT Genomics Business
EncrypGen
(https://encrypgen.com/)
Gene Blockchain
(http://www.geneblockchain.org)
Genecoin
(http://genecoin.me/)
Genomes.io (https://genomes.io/)
Nebula Genomics
(https://nebula.org/)
Shivom (https://www.shivom.io/)
Zenome
(https://zenome.io/about/)

Objective
DLT-based genome data market
DLT-based genome data market
Permanent storage of one’s
DNA using Bitcoin
DLT-based genome data market
DLT-based genome data market
DLT-based genome data market
DLT-based genome data market

in-genomics space, Nebula Genomics aims to offer
direct-to-consumer genetic testing services, while at the
same time creating a genome data market where the very
same consumers can trade their genome data with
interested
third-parties
(e.g.,
researchers,
pharmaceutical companies) in exchange for tokens of
Nebula Genomics’ own crypto currency [21]. Similarly,
EncrypGen, Gene Blockchain, Genomes.io, Shivom,
and Zenome are also operating or planning to operate
their own DLT-based genome data market together with
their own cryptocurrency. A notable exception to the
aforementioned businesses is Genecoin. Compared to
the majority of businesses whose aim is to build DLTbased genome data markets, Genecoin aims at creating
a permanent storage for individuals’ DNA by storing
their genome data in the Bitcoin network. Instead of
giving out a Genecoin cryptocurrency, consumers are
encouraged to create their own personal cryptocurrency
off of their Bitcoin seed. Table 1 provides a nonexhaustive summary of the main players in the
commercial DLT-in-genomics space.
Looking at scientific literature related to the
application of DLT in genomics, we see that this stream
of research is in a state of emergence (see Table 2).
While an increasing number of research articles on DLT
in health care is published, some of which also address
the case of genomics [e.g., 22, 23, 24], we are aware of
only four publications that explicitly focus on the
peculiarities of bringing DLT into genomics. The
viewpoint articles of Ozercan, et al. [6] and Shabani [4]
and Thiebes, et al. [25] all provide a general discussion
of potential that DLT holds for the genomics
community. In addition, Ozercan, et al. [6] also describe
the prototype of a DLT-based research infrastructure for
genomics, called Coinami. In this infrastructure,
research institutes may place genomics-related research
jobs (e.g., genome sequence alignment) on the
distributed ledger, which are then executed by nodes
(so-called miners) that are rewarded with tokens via a
coinbase transaction in return. Lee, et al. [5] on the other
hand develop a DLT-based lossless compression

platform for genome data. Here DLT is used as a means
for handling data exchange requests. Interestingly,
although a variety of different DLT-concepts exists
(e.g., Blockchain, TDAG, BlockDAG), current
discourses in research and practice on the application of
DLT in genomics center around Blockchain only.

3. Methods
In order to identify salient opportunities and
challenges related to the application of DLT in
genomics, as well as their relative importance, we
conduct a ranking-type Delphi study. We provide details
on the Delphi panel selection and each of the three
Delphi phases below.

3.1. Panel selection
Delphi studies typically rely in the input of experts
with profound knowledge on the phenomenon under
consideration (here DLT in genomics) [26]. Towards
this end, we identified three groups of experts that could
aid in the identification of challenges and opportunities
for the application of DLT in genomics: (1) experts on
DLT with at least basic knowledge on genomics; (2)
experts on genomics with at least basic knowledge on
DLT; and (3) individuals with high expertise in both,
DLT and genomics.
Literature provides thresholds of 7 to 30
knowledgeable experts that are necessary to generate
meaningful insights using Delphi [27]. To recruit an
adequate number of experts from the three relevant
groups, we employed a purposeful sampling strategy
[28] and used different techniques to contact potential
participants. First, we contacted the founders and
employees (whom we assumed to have the required
expertise) of the several DLT-in-genomics businesses
Table 2. Literature on DLT in genomics.
Article
Type
Lee, et al. [5] Original
article
Mackey, et al. Viewpoint
[22]
RomanViewpoint
Belmonte, et
al. [23]
Ozercan, et al. Viewpoint
[6]
Shabani [4]

Viewpoint

Talukder, et
al. [24]

Original
article

Thiebes, et al. Viewpoint

Research Focus
Development of DLT-based lossless
compression platform for genome data
Challenges and opportunities for DLT in
health care (genome data discussed as an
example)
Discussion of the transformatory
potential of DLT for health care (genome
data discussed as an example)
Discussion of the transformatory
potential of DLT for genomics / proposal
of a DLS for genomics
Discussion of the transformatory
potential of DLT for genomics
Development of a consensus protocol for
DLT-based electronic health records
(genome data discussed as an example)
Discussion of the transformatory
potential of DLT for genomics
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(see Table 1) via email, contact forms on their websites,
and social networks. We also reached out to authors of
white papers on this topic (many of which overlapped
with the founders and employees of the previously
named startups), researchers who had previously
published articles on DLT genomics (see Table 2), and
industry and international research consortia (i.e. The
Global Alliance for Genomics and Health, and
FORCE11). Lastly, we used personal contacts to
researchers of whom we knew had some relevant
experience and snowballing to recruit additional
experts. Overall, this sampling strategy resulted in 12
actual participants for the brainstorming phase. Table
A1 in the appendix provides and overview of relevant
demographics for these participants.

We conducted the entire study over the Internet by
means of an online survey software for the questionnaire
rounds and email to communicate with our participants
after the brainstorming phase.

each database with the following string in title, abstracts
and keywords: (“distributed ledger technolog*” OR
“blockchain*” OR “DLT”) AND (“genom*” OR
“genetic*” OR “DNA” OR “proteonomic*”) and
limited our search to peer-reviewed articles to ensure
high quality of articles. Our search yielded 573 articles,
of which we deemed only five relevant for this research.
We also included eight available white papers of
relevant businesses. Subsequently, two researchers
coded potential opportunities and challenges in these
articles and white papers independently and compared
their results.
The data consolidation process and literature review
resulted in a list of 17 opportunities and 15 challenges
for the application of DLT in genomics. In order to
ensure that participants’ thoughts were adequately
captured and represented in the consolidated list, we
asked participants to approve the list of opportunities/
challenges as suggested by Paré, et al. [27]. Participants’
feedback led to minor adjustments, (e.g., rephrasing
certain aspects), but did not result in adding new or
removing existing opportunities/challenges.

3.2.1. Brainstorming phase. At the beginning of the
brainstorming phase we introduced participants to the
Delphi procedure as well as to DLT and genomics in
order to establish a common understanding for both
concepts. Drawing on previous ranking-type Delphi
studies [16, 26], we next asked participants to name and
briefly describe three to ten opportunities and challenges
for the application of DLT in genomics. We also gave
participants the possibility to proceed with the
questionnaire in case they did not want to provide three
opportunities or challenges (e.g., some participants were
only able to name one opportunity but multiple
challenges, or vice versa). At the end of the
brainstorming questionnaire we asked participants to
provide basic demographic information and an email
address so that we could invite them for the subsequent
Delphi phases.
Overall, participants provided us with 33 entries for
potential opportunities and 39 entries for potential
challenges. We consolidated the set of responses by
manually aggregating duplicate responses, unifying
terminology, and grouping similar opportunities/
challenges [27, 29]. In order to augment the lists of
opportunities and challenges, we further conducted a
review of related literature and white papers. To identify
scientific publications addressing the use of DLT in
genomics, we searched pertinent scientific databases
that cover a wide range of journals and conferences:
ACM Digital Library, EBSCOhost, IEEE Xplore,
ProQuest, ScienceDirect, and PubMed. We searched

3.2.2. Narrowing down and ranking phases. Extant
literature suggests 20 or less items for the ranking phase
[29], since a large number of items reduces participants
ability to properly distinguish the ranks of individual
items [30]. The brainstorming phase yielded less than 20
opportunities as well as less than 20 challenges. Thus,
and in an attempt to reduce panel attrition, we decided
to skip the narrowing down phase and directly proceed
to the ranking phase, although the narrowing down
phase might in some cases provide additional insights.
In the ranking phase, we presented the 17
opportunities and 15 challenges in random order and
asked participants to rank them according to the
following rationales: For the opportunities, we asked
participants to rank them with regard to their value for
the genomics community from highest to lowest. For the
challenges, we asked participants to rank them with
respect to which challenges deserve the genomics
community’s attention and resources from most to least.
Participants were also asked to justify their rankings,
although this was not mandatory and could be skipped.
We used Kendall’s coefficient of concordance (W) to
measure the degree of consensus between the experts’
rankings (Paré et al. 2013; Schmidt 1997; Singh et al.
2009). It attains values between 0 and 1, whereby
consensus is considered strong for W ≥ 0.7, moderate
for 0.7 > W ≥ 0.5, and weak for 0.5 > W ≥ 0.3 (Schmidt
1997). For lower values no consensus is presumed.
Moreover, a Friedman test was used to calculate the
mean rank for each opportunity/challenge (Friedman

3.2. Data collection and analysis methods
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1937). Nine participants signaled their willingness to
participate in additional Delphi rounds after the
brainstorming phase, with only 3 actually completing
the ranking phase by the time of writing this paper.

4. Results
Based on the inputs of experts during the Delphi
study and our literature review, we were able to identify
17 opportunities (see Tab. 3) and 15 challenges (see
Tab. 4) for the application of DLT in genomics. In order
to structure identified opportunities and challenges, we
drew on the TOE-framework [31] and categorized
opportunities and challenges into technology (i.e.,
opportunities/challenges related to the technology
itself), organization (i.e., opportunities and challenges
related to organizational structures of the genomics
community), and environment (opportunities and
challenges related to factors that are external to the
genomics community).

4.1. Opportunities for DLT in genomics
4.1.1. Technology. Most identified opportunities (9 out
of 17) belong to the technology category. Owing to the
inherent characteristics of genome data and their high
sensitivity, protection of genetic privacy is a major
objective in genomics. Consequently, we identified
several technological opportunities for DLT in
genomics that support the protection of data owners’
genetic privacy. DLT, for example, warrants high
degrees of confidentiality by ensuring that genome data
is only disclosed to third parties with consent of the data
owner. Likewise, and completing the so-called CIA
triad, DLT also warrants high degrees of integrity by
ensuring that genome data is not altered without data
owners’ prior agreement, as well as high degrees of
availability of DLT-based platforms and services (and
thus genome data) due to being inherently decentralized
and removing single points of failure. On the one hand
DLT further enables data owners to maintain their
genome data anonymously, meaning that the tracing of
data owners’ real identities requires a prohibitive
amount of effort, while on the other hand also affording
high levels of transparency by ensuring the traceability
of all actions performed on the data. From the
perspective of data users (e.g., researchers, medical
professionals, insurers) the durability as well as the
accuracy of genome data records are important factors
for an effective use of such data. Towards this end DLT
affords the establishment of a permanent genome data
record (opportunity: durability), as well as verifying the

correctness of genome data (opportunity: data
accuracy). Adding to this, DLT-based systems reduce
storage requirements for those in charge of governing
the genome data by enabling their distributed storage.
Finally, many contemporary DLT concepts rely on
compute intensive tasks as part of their consensus
protocols (e.g., proof-of-work). DLT therefore might
allow for the solving of compute intensive tasks in
genomics by enabling the distribution of compute tasks
to nodes of a DLT network, for example, as part of the
proof-of-work principle.
4.1.2. Organization. We categorized 7 out of the 17
opportunities into the organization category. Based on
its distributed and decentralized nature, DLT eliminates
the need for central authorities. Thus, it supports
decentralization within the genomics community by, for
example, helping to break up extant data silos or
affording the removal of (costly) intermediaries. While
the current genomics ecosystem is relatively closed with
several large closed-access databases and limited
possibilities for individuals to actively participate, the
openness of DLT (i.e., many DLT-based systems are
open to everyone) promotes the active participation of
all stakeholders (e.g., researchers, data owners) in the
generation, sharing, and processing of genome data.
Another frequent problem within genomics pertains to
heterogeneity of different information systems, which
often hinders effective exchange of genome data
between
different
entities.
DLT
supports
interoperability by facilitating the standardization of
technologies and policies. Similarly, many processes in
genomics (especially the granting and revocation of
consents) are complex and tedious. DLT supports the
formalization and subsequently automatic execution of
processes in genomics through the utilization of smart
contracts. An often-raised question about genome data
relates to the ownership of the data. To this end, DLT
not only allows to enforce property rights over personal
genome data by enabling the verification and
administration of said property rights, but also gives
data owners direct control over their data, by enabling
data owners to grant and revoke access rights to their
genome data flexibly and on-demand, based on their
changing data sharing and access preferences. Closely
related to the question of ownership is the question of
how to reimburse entities for the disclosure or
processing of genome data. Thereby, application of
DLT in genomics allows for the creation of a token
economy, which enables the exchanging of value in the
form of tokens (e.g., monetary value, access to services)
for the disclosure and/or processing of genome data.
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Table 3. Opportunities for DLT in genomics.

Env.

Organization

Technology

Cat. Opportunity
Src
Anonymity. DLT enables data owners to maintain (e.g., store, share) their (genome) data without their real identities being traceable
since it is either not possible or requires unreasonable efforts.
Availability. DLT increases the probability to which a DLT-based (genome) data platform or service can be reached in a fully
functioning condition, due to it being a decentralized system.
Confidentiality. DLT is capable of ensuring that (genome) data is only disclosed to third parties with consent of the data owner, where
the data owner defines the granularity and form of the (genome) data.
Data accuracy. DLT allows to verify the correctness of (genome) data.
Data storage. DLT reduces data storage requirements for individual data owners by enabling the distributed storage of (genome) data. ◑

●
●
●
●

Distributed computing. DLT allows the solving of compute-intensive problems by enabling the distribution of compute tasks to nodes
of a DLT network (e.g., as part of proof-of-work).
Durability. DLT affords the establishment of a permanent (genome) data record.
Integrity. DLT is capable of ensuring that (genome) data is not altered without prior agreement of the data owners.
Transparency. DLT affords the traceability of the handling of (genome) data (e.g., data access, data processing, data search) by means
of logging all performed actions.
Decentralization. DLT eliminates the need for central authorities, thus helping to break up data silos and affording the removal of
intermediaries.
Flexibility. DLT enables the on-demand granting and revocation of access rights to (genome) data based on data owners' changing data
sharing and access preferences.
Interoperability. DLT supports the exchange of (genome) data among different information systems by means of facilitating
standardization of technologies and policies.
Openness. DLT promotes the active participation of all stakeholders (e.g., researchers, data owners) in the generation, sharing, and
processing of (genome) data.
Ownership. DLT allows for the verification and administration of property rights on personal (genomic) data.
Process automation. DLT affords the formalization of processes in genomics through smart contracts for the purpose of automating
these processes.
Token economy. DLT enables the exchanging of value via of tokens (e.g., monetary value, access to services) for the disclosure and/or
processing of (genome) data.
Interdependent privacy. DLT allows to enforce that relatives approve of a data owner sharing their genome data by means of smart
contracts.

Column Source: ◐ = opportunity originated from brainstorming phase only; ◑ = opportunity originated from literature review only;
opportunity originated from brainstorming phase and review

4.1.3. Environment. Finally, one opportunity belongs
to the environment category. Kinship is a central
characteristic of genome data, meaning that blood
relatives share certain genetic traits with each other [15].
This could potentially also impede the privacy of blood
relatives when sharing one’s genome data. DLT
supports the preservation of such interdependent
privacy by requiring that affected relatives approve of
one sharing their genome data prior to the actual
sharing.

4.2. Challenges for DLT in genomics
4.2.1. Technology. Similar to the opportunities, the
majority of challenges (7 out of 15) belong to the
technology category. Although DLT receives
tremendous attention from research and practice it is
still a relatively immature technology with many
unresolved questions and issues. Especially in terms of
security and the sensitivity of genome data, technology
maturity or more precisely the lack thereof remains an
issue. Adding to this, data handling (i.e., the retrieval
and management of genome data) and data storage are
two challenges deeply rooted in DLT characteristics.

◑

●
●
●
●
●
◑

●
◑

●
●
◐

●

=

Most DLT-concepts were designed for small
transactional data and are unable to store genomicssized data sets on ledger [4, 6]. Furthermore, current
implementations of DLT lack the capabilities to
efficiently query genome data (e.g., accessing arbitrary
parts of a dataset or streaming data). Towards this end,
many extant proposals for DLT-based platforms in
genomics are also based on Blockchain, whose primary
consensus protocols are based on proof-of-work, which
relies on compute-intensive tasks. Although other less
resource-consuming consensus mechanisms (e.g.,
proof-of-stake) have been proposed, the dominance of
inefficient consensus protocols wastes precious
computing resources that could be used for solving
genomics-related problems instead. As pointed out
before, ensuring integrity of data is an often-cited
opportunity of DLT. However, at the same time DLT’s
rigidness could also pose a serious challenge in terms of
integrity, namely if those rightfully interested in
changing data are being hindered to do so (e.g., due to
prohibitively expensive consensus mechanisms or
simply a lost encryption key).
Similar to integrity, durability was not only
identified as an opportunity but also as a challenge. Due
to rigidness of DLT-based systems and data replication,
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Table 4. Challenges for DLT in genomics.

Env.

Organization

Technology

Cat. Challenge
Src
Data handling. DLT-based systems are not designed to retrieve or manage high volumes of (genome) data efficiently.
Data storage. DLT-based systems are not designed to store genomics-size data sets on-ledger.
Durability. Disclosing (genome) data via DLT is a permanent, difficult-to-reverse decision.
Efficiency. Consensus mechanisms in DLT-based systems such as proof-of-work waste computing resources.
◑
Integrity. Altering (genome) data that is stored, shared, or managed via DLT-based systems might require much effort or be impossible.
Technology maturity. DLT is an immature technology with potential security issues.
Transparency. Transparency of distributed ledger systems might impede individuals' privacy.
Conflicting interests. Different stakeholders might have conflicting interests, which are impossible to resolve.
Ease of use. Getting, maintaining, and managing access to (genome) data via DLT requires much effort.
Interoperability. Effective use of DLT for genomics requires interoperability between a multitude of diverse information systems.
Novelty. DLT is largely unknown to the genomics community and poorly understood.
Token economy. Rewarding data owners with tokens for sharing their (genome) data can incentivize mindless data sharing.
◐
Emergency access. Situations that require access to health-related data by third parties without data owners' prior approval (e.g., by ◑
medical professionals in an emergency, when data owners are unconscious), might violate foundational principles of DLT.
Openness. Openness of DLT-based systems can result in new attack vectors and misuse of the system and stored (genome) data.
Uncertain regulation. Regulations around DLT and genetic privacy are constantly changing and evolving differently in different parts
of the world.
Column Source: ◐ = challenge originated from brainstorming phase only; ◑ = challenge originated from literature review only;
● = challenge originated from brainstorming phase and review

●
●
●
●
●
●
●
●
●
●
●
●

completely removing information that has once been
stored from the system is difficult and, in many cases,
impractical. Another often cited opportunity for the
application of DLT in genomics is transparency. Yet,
such uncompromising transparency could also impede
individuals’ privacy by providing information or
enabling the deduction of information that one does not
wish to be available to others (e.g., logs of an individual
sharing their genome data with a cancer research center
could indicate that this person suffers from cancer).

conflicting interests, which could be difficult or
impossible to resolve. From an ethical point of view,
rewarding data owners with tokens for sharing their
genome data might result in mindless data sharing. Due
to the unique characteristics of genome data, future uses
and potential avenues for privacy infringements are
difficult to foresee, even for professionals. Introducing
monetary incentives into this ecosystem could
encourage data sharing without being able to adequately
assess the potential issues.

4.2.2. Organization. We categorized five challenges as
organizational challenges. While we identified
technology maturity as a technology-related challenge,
novelty of DLT also poses a challenge to the genomics
community itself as its benefits and risks are largely
unknown or at least poorly understood. Not only might
this lead to ineffective implementations but also to
outright rejection of this technology. Likewise, getting,
maintaining, and managing access to DLT-based
systems still requires comparably much effort. Overall,
most DLT-based systems still suffer from poor ease of
use, which could also hinder adoption within the
genomics community. The effective application of DLT
within genomics requires interoperability between a
multitude of diverse information systems. Although
DLT could facilitate standardization of technologies and
policies within genomics, the current situation is far
from this ideal, essentially creating a chicken-and-egg
problem in terms of interoperability. Adding to this,
effective application of DLT also requires the
formalization of certain aspects (e.g., access
requirements). Here, different stakeholders might have

4.2.3. Environment. Lastly, the environment category
comprises three challenges. A frequent requirement
within health information technology is a so-called
emergency access, where in cases of emergency medical
professionals are granted access to patient data without
their prior consent. Such access might violate
fundamental principles of DLT and could be impossible
or at least be highly difficult to realize. Next, openness
refers to the system promoting the active participation
of involved stakeholders. However, at the same time
such an open system design could also invite malicious
users into the system and result in new attack vectors or
the misuse of the system and especially stored genome
data. The third and last challenge in this category refers
to uncertain regulation. Since DLT is a relatively young
technology its true benefits as well as its problems for
societies around the globe are largely unknown. In an
attempt to keep up with the rapid technological
advances, regulation in different parts of the world is
constantly changing and adapting to the new
technological realities. Consequently, changes in
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Table 5. First round rankings.
Opportunity
Confidentiality
Ownership
Flexibility
Decentralization
Openness
Interdependent privacy
Anonymity
Transparency
Durability
Interoperability
Availability
Integrity
Data accuracy
Distributed computing
Token economy
Process automation
Data storage

Mean rank
4.00
4.33
5.67
6.33
6.67
7.00
7.67
9.00
9.67
10.00
10.33
10.67
11.33
11.67
12.33
12.67
13.67

Challenge
Uncertain regulation
Durability
Ease of use
Emergency access
Novelty
Technology maturity
Openness
Efficiency
Integrity
Interoperability
Token economy
Data storage
Transparency
Conflicting interests
Data handling

Mean rank
1.33
5.67
6.00
6.00
6.00
6.00
6.33
8.67
9.33
9.67
10.00
10.33
10.33
11.00
13.33

Overall rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Kendall’s W = 0.346
Overall rank
1
2
3
3
3
3
7
8
9
10
11
12
12
14
15
Kendall’s W = 0.450

regulation around the world could render certain
applications of DLT illegal or impossible.

4.3. Ranking of opportunities and challenges
Based on the inputs we received from our panel so far,
the top three opportunities are (1) confidentiality, (2)
ownership, and (3) flexibility, whereas the top three
challenges are (1) uncertain regulation, (2) durability,
and (3) ease of use. Although Kendall’s W must be
considered low for both rankings (WOpportunities = 0.346,
WChallenges = 0.450), overall consensus seems to be
higher for the challenges ranking. Table 5 shows the
mean ranks as well as the resulting overall ranks of the
first round for all elicited opportunities and challenges.

5. Discussion
5.1. Principal findings
The objective of this research was to identify salient
opportunities and challenges for the application of DLT
in genomics. To this end, we conducted a ranking-type

Delphi study with an international panel of experts and
augmented the results of the brainstorming phase with a
comprehensive literature review, which altogether
yielded 17 diverse opportunities as well as 15 diverse
challenges for the application of DLT in genomics.
Consistent with current efforts on DLT in genomics, our
Delphi study and literature review yielded token
economy as one potential opportunity. However,
contrary to the currently predominant focus on the use
of DLT to establish genome data markets, results of our
Delphi study also yielded several opportunities deemed
more important than the creation of a token economy
(e.g., confidentiality, ownership, or flexibility).
Furthermore, uncertain regulation was by far deemed as
the most important challenge, which is also consistent
current debates around the application of DLT in critical
contexts such as health care or finance. Since DLT has
received tremendous attention from researchers and
practitioners in the health care sector [23], an obvious
question is whether the opportunities and challenges
presented here are unique to genomics. While many of
the opportunities and challenges certainly also apply to
health care in general, we also see some opportunities
(e.g., interdependent privacy) and challenges (e.g., data
handling and data storage) that are unique or at least
more relevant to the genomics context. Moreover, the
relative rankings of individual opportunities and
challenges might be different for the genomics context
than for a general health care context.
Interestingly, many of the identified opportunities
were at the same time also named as a potential
challenge. A prime example for this is transparency,
which overall might be an opportunity for the genomics
community but could at the same time also infringe
individuals’ privacy. We think that there are two
potential reasons for this that can also be found in the
presented challenges. First, DLT is a novel and still
poorly understood phenomenon in the genomics
community. With time and increasing knowledge about
DLT, we might be able to address several challenges,
transforming them into pure opportunities. Second,
many of the conflicting interests between the diverse
stakeholders involved in genomics might be
unresolvable, creating a reality in which the very same
DLT characteristic is an opportunity for some
stakeholders, while being a challenge to others.
Looking at the sources of identified opportunities
and challenges, we see that most opportunities (12 out
of 17) as well as most challenges (12 out of 15) were
actually named in both, the brainstorming phase of our
Delphi study and in extant literature. Although this
surprising finding seemingly contradicts our initial
statement that current discussions about DLT in

Page 3282

genomics are predominantly positive, it must be noted
that potential challenges were often only named
implicitly. Moreover, sections discussing potential
challenges were rather short and often downplayed
named challenges.

5.2. Implications
Our work has several implications for research and
practice. For practitioners, including those researchers
enticed by the utilization of DLT for their work, our
research highlights several benefits brought forward by
the application of DLT. It especially shows that there are
many benefits of DLT beyond the creation of mere data
markets. However, our results also show the presence of
a diverse set of challenges that need to be overcome in
order to realize the full potential of DLT in genomics.
Those interested in the utilization of DLT in genomics
should therefore develop strategies to address the most
pressing challenges.
For research, we are among the very first to
systematically elicit opportunities and especially
challenges for the nascent phenomenon that is DLT in
genomics, as well as their relative importance. We
thereby add to research a better and contextualized
understanding of DLT. In particular, we strengthen the
importance of genomics as a research context for the
application of DLT that, although similar to the
application of DLT in general health care, possesses
some unique features like interdependent privacy issues.
We also highlight the very existence of the dual roles of
some opportunities that at the same time are regarded as
challenges (or vice versa). Starting from here,
researchers enticed by the application of DLT in
genomics can use our lists of opportunities and
challenges to further investigate specific opportunities
or
challenges.
The
dual
role
of
some
opportunities/challenges also warrants further, in-depth
investigations.

5.3. Limitations and future research
Despite this study being a first step towards a more
nuanced contemplation of the application of DLT in
genomics, our research is not without limitations. First,
the results presented in this study are to a large degree
based on the inputs of a limited number of experts. This
is mainly due to the fact that there is a shortage of
professionals with expertise in DLT and genomics and
that many experts, especially those working for
businesses in the DLT-in-genomics space, did not
respond to our invitations. Although the number of

experts who participated in our study is within
established thresholds, we tried to account for this
limitation by also conducting a comprehensive review
of related white papers and research articles. We are
thus confident that our results provide a comprehensive
picture of the opportunities and challenges for DLT in
genomics. Another limitation of our work pertains to the
fact that so far only 3 experts completed the first ranking
phase, which is why our rankings must be considered
preliminary at best. Although such high panel attrition
is not uncommon in Delphi studies, we will continue to
invite the remaining experts to complete the ranking and
also investigate other means (e.g., a survey) to establish
a more robust ranking of the presented opportunities and
challenges. Towards this end, and drawing on the
conflicting interests challenge, future research should
also investigate the potential existence of different
relative rankings of the presented opportunities and
challenges for different stakeholders in genomics.

6. Conclusion
Although DLT has recently emerged as a hot topic
within the genomics community, little is known about
the actual opportunities and challenges for the
application of DLT in genomics. Within this research
we systematically elicited 17 opportunities and 15
challenges for DLT in genomics as well as their relative
importance. Thereby, we make important contributions
to practice and research. For practice, we highlight
application opportunities for DLT in genomics beyond
genome data markets as well as important potential
pitfalls that need to be addressed. For research, we
underline genomics as a promising application area for
DLT and support a more nuanced, less hyped view of
this phenomenon. We also lay the foundations for
researchers interested in differences between the
application of DLT in genomics and in health care in
general.
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8. Appendix
Table A1. Delphi Panel Characteristics.
Characteristics
Sex
Age (years)
Nationality
Experience in
genomics (years)
Experience in DLT
(years)

Panel profile (n=12)
Female: 25,00%
Male: 75,00%
Avg.: 43
Min.: 29;
Max.: 66
U.S.: 25,00%
German: 16,67%
Other: 8,33%
Avg.: 7,25
Min.: 1;
Max.: 25
Avg.: 2,79
Min.: 0;
Max.: 12
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